## **Antonis S Manolis**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2555669/publications.pdf

Version: 2024-02-01

280 papers

39,322 citations

50276 46 h-index 194

g-index

288 all docs 288 docs citations

288 times ranked

28079 citing authors

#	Article	IF	CITATIONS
1	Sodium-glucose cotransporter type 2 inhibitors and cardiac arrhythmias. Trends in Cardiovascular Medicine, 2023, 33, 418-428.	4.9	10
2	Takotsubo Syndrome and Sudden Cardiac Death. Angiology, 2023, 74, 105-128.	1.8	4
3	The proarrhythmic conundrum of alcohol intake. Trends in Cardiovascular Medicine, 2022, 32, 237-245.	4.9	13
4	Lipoprotein(a) and Cardiovascular Disease: A Missing Link for Premature Atherosclerotic Heart Disease and/or Residual Risk. Journal of Cardiovascular Pharmacology, 2022, 79, e18-e35.	1.9	15
5	Atrial fibrillation-induced tachycardiomyopathy and heart failure: an underappreciated and elusive condition. Heart Failure Reviews, 2022, 27, 2119-2135.	3.9	7
6	Gut Microbiota and Cardiovascular Disease: Symbiosis Versus Dysbiosis. Current Medicinal Chemistry, 2022, 29, 4050-4077.	2.4	14
7	Low serum albumin: A neglected predictor in patients with cardiovascular disease. European Journal of Internal Medicine, 2022, 102, 24-39.	2.2	49
8	Diet and Sudden Death: How to Reduce the Risk. Current Vascular Pharmacology, 2022, 20, 383-408.	1.7	2
9	Effect of the COVID-19 pandemic on cardiac electrophysiological ablation procedures in Greece – data from the Hellenic Society of Cardiology Ablation Registry. Hellenic Journal of Cardiology, 2022, 67, 76-76.	1.0	1
10	Trends in ablation procedures in Greece over the 2008-2018 period: Results from the Hellenic Cardiology Society Ablation Registry. Hellenic Journal of Cardiology, 2021, 62, 48-54.	1.0	2
11	Mitochondrial dysfunction in cardiovascular disease: Current status of translational research/clinical and therapeutic implications. Medicinal Research Reviews, 2021, 41, 275-313.	10.5	51
12	COVID-19 Infection: Viral Macro- and Micro-Vascular Coagulopathy and Thromboembolism/Prophylactic and Therapeutic Management. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 12-24.	2.0	80
13	COVID-19 and Acute Myocardial Injury and Infarction: Related Mechanisms and Emerging Challenges. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 107424842110110.	2.0	14
14	Incidence, electrophysiological characteristics, and longâ€ŧerm followâ€up of perimitral atrial flutter in patients with previously confirmed mitral isthmus block. Journal of Arrhythmia, 2021, 37, 584-596.	1.2	3
15	The Cardiovascular Benefits of Caffeinated Beverages: Real or Surreal? / "Metron Ariston - All in Moderation― Current Medicinal Chemistry, 2021, 28, .	2.4	5
16	The role of the autonomic nervous system in cardiac arrhythmias: The neuro-cardiac axis, more foe than friend?. Trends in Cardiovascular Medicine, 2021, 31, 290-302.	4.9	45
17	Cardiovascular implications and complications of the coronavirus disease-2019 pandemic: a world upside down. Current Opinion in Cardiology, 2021, 36, 241-251.	1.8	5
18	Electrocardiography of cardiac resynchronization therapy: Pitfalls and practical tips. Journal of Cardiovascular Electrophysiology, 2021, 32, 3228-3244.	1.7	2

#	Article	IF	Citations
19	Update on Cilostazol: A Critical Review of its Antithrombotic and Cardiovascular Actions and its Clinical Applications. Journal of Clinical Pharmacology, 2021, , .	2.0	7
20	COVID-19 Infection: A Neuropsychiatric Perspective. Journal of Neuropsychiatry and Clinical Neurosciences, 2021, 33, 266-279.	1.8	6
21	COVID-19 infection and body weight: A deleterious liaison in a J-curve relationship. Obesity Research and Clinical Practice, 2021, 15, 523-535.	1.8	18
22	Subclinical thyroid dysfunction and cardiovascular consequences: An alarming wake-up call?. Trends in Cardiovascular Medicine, 2020, 30, 57-69.	4.9	41
23	Congenital heart block: Pace earlier (Childhood) than later (Adulthood). Trends in Cardiovascular Medicine, 2020, 30, 275-286.	4.9	22
24	2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 655-720.	2.2	647
25	Methylmalonic acid and vitamin B12 in patients with heart failure. Hellenic Journal of Cardiology, 2020, 61, 330-337.	1.0	18
26	Editorial commentary: Premature heart disease mortality: A sobering reality calling for action. Trends in Cardiovascular Medicine, 2020, 30, 375-377.	4.9	1
27	Proton pump inhibitors and cardiovascular adverse effects: Real or surreal worries?. European Journal of Internal Medicine, 2020, 72, 15-26.	2.2	15
28	The Controversy of Renin–Angiotensin-System Blocker Facilitation Versus Countering COVID-19 Infection. Journal of Cardiovascular Pharmacology, 2020, 76, 397-406.	1.9	16
29	COVID-19 infection and cardiac arrhythmias. Trends in Cardiovascular Medicine, 2020, 30, 451-460.	4.9	90
30	Nursing intervention and quality of life in patients undergoing invasive cardiac procedures. Hellenic Journal of Cardiology, 2020, 62, 256-259.	1.0	0
31	Myocardial infarction or acute coronary syndrome with non-obstructive coronary arteries and sudden cardiac death: a missing connection. Europace, 2020, 22, 1303-1310.	1.7	17
32	Cardio-Rheumatology: Cardiovascular Complications in Systemic Autoimmune Rheumatic Diseases / Is Inflammation the Common Link and Target?. Current Vascular Pharmacology, 2020, 18, 425-430.	1.7	3
33	Cardiac arrhythmias in pregnant women: need for mother and offspring protection. Current Medical Research and Opinion, 2020, 36, 1225-1243.	1.9	4
34	Atrial Fibrillation and Cognitive Impairment: An Associated Burden or Burden by Association?. Angiology, 2020, 71, 498-519.	1.8	19
35	Cardiovascular Disease in Antiphospholipid Syndrome. Current Vascular Pharmacology, 2020, 18, 538-548.	1.7	6
36	Cardiovascular Risk of Synthetic, Non-Biologic Disease-Modifying Anti- Rheumatic Drugs (DMARDs). Current Vascular Pharmacology, 2020, 18, 455-462.	1.7	4

3

#	Article	IF	CITATIONS
37	Cardiovascular Complications of Sleep Disorders: A Better Night's Sleep for a Healthier Heart / From Bench to Bedside. Current Vascular Pharmacology, 2020, 19, 210-232.	1.7	23
38	Cardio-Rheumatology: Two Collaborating Disciplines to Deal with the Enhanced Cardiovascular Risk in Autoimmune Rheumatic Diseases. Current Vascular Pharmacology, 2020, 18, 533-537.	1.7	3
39	Cardiovascular Safety of Psychiatric Agents: A Cautionary Tale. Angiology, 2019, 70, 103-129.	1.8	20
40	Neprilysin Inhibitors: Filling a Gap in Heart Failure Management, Albeit Amidst Controversy and at a Significant Cost. American Journal of Cardiovascular Drugs, 2019, 19, 21-36.	2.2	3
41	Pulmonary vein reconnection following cryo-ablation: Mind the "Gap―in the carinae and the left atrial appendage ridge. Indian Pacing and Electrophysiology Journal, 2019, 19, 125-128.	0.6	6
42	Cardiac amyloidosis: An underdiagnosed/underappreciated disease. European Journal of Internal Medicine, 2019, 67, 1-13.	2.2	29
43	Recommending marijuana use: Violation of the Hippocratic aphorism of "do good or do no harm― European Journal of Internal Medicine, 2019, 61, e14-e15.	2.2	1
44	Sudden death in heart failure with preserved ejection fraction and beyond: an elusive target. Heart Failure Reviews, 2019, 24, 847-866.	3.9	25
45	Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men's Issue?. Current Hypertension Reports, 2019, 21, 22.	3.5	25
46	Winter Swimming: Body Hardening and Cardiorespiratory Protection Via Sustainable Acclimation. Current Sports Medicine Reports, 2019, 18, 401-415.	1.2	17
47	<p>Spotlight on Spironolactone Oral Suspension for the Treatment of Heart Failure: Focus on Patient Selection and Perspectives</p> . Vascular Health and Risk Management, 2019, Volume 15, 571-579.	2.3	7
48	Cardiovascular effects of alcohol: A double-edged sword / how to remain at the nadir point of the J-Curve?. Alcohol, 2019, 76, 117-129.	1.7	28
49	Sudden unexpected death in epilepsy: The neuro-cardio-respiratory connection. Seizure: the Journal of the British Epilepsy Association, 2019, 64, 65-73.	2.0	70
50	Psoriasis and cardiovascular disease: the elusive link. International Reviews of Immunology, 2019, 38, 33-54.	3.3	32
51	Effect of PR interval and pacing mode on persistent atrial fibrillation incidence in dual chamber pacemaker patients: a sub-study of the international randomized MINERVA trial. Europace, 2019, 21, 636-644.	1.7	20
52	Focal atrial tachycardia ablation: Highly successful with conventional mapping. Journal of Interventional Cardiac Electrophysiology, 2019, 55, 35-46.	1.3	9
53	Editorial commentary: Prior silent/unrecognized myocardial infarction and heart failure: Size/extent matters. Trends in Cardiovascular Medicine, 2019, 29, 245-247.	4.9	0
54	Use of intravenous vernakalant for atrial fibrillation conversion in the regular ward under only bedside monitoring. Hellenic Journal of Cardiology, 2019, 60, 54-56.	1.0	6

#	Article	IF	CITATIONS
55	Cannabis Associated "High―Cardiovascular Morbidity and Mortality: Marijuana Smoke Like Tobacco Smoke? A Déjà Vu/Déjà Vécu Story?. Mini-Reviews in Medicinal Chemistry, 2019, 19, 870-879.	2.4	11
56	Is Atherothromboaspiration a Possible Solution for the Prevention of No-Reflow Phenomenon in Acute Coronary Syndromes? Single Centre Experience and Review of the Literature. Current Vascular Pharmacology, 2019, 17, 164-179.	1.7	2
57	Pharmacologic inhibition of the mitochondrial Na+/Ca2+ exchanger protects against ventricular arrhythmias in a porcine model of ischemia-reperfusion. Hellenic Journal of Cardiology, 2018, 59, 217-222.	1.0	10
58	Percutaneous retrieval of a dislodged Amplatzer septal occluder device from the pulmonary artery with sole use of a snare and device lassoing. Hellenic Journal of Cardiology, 2018, 59, 57-59.	1.0	6
59	Simplified percutaneous closure of patent foramen ovale and atrial septal defect with use of plain fluoroscopy: Single operator experience in 110 consecutive patients. Indian Heart Journal, 2018, 70, 24-31.	0.5	7
60	Electrophysiology Catheter-Facilitated coronary sinus cannulation and implantation of cardiac resynchronization therapy systems. Hellenic Journal of Cardiology, 2018, 59, 26-33.	1.0	9
61	Cardiovascular Safety of Antihyperglycemic Agents: "Do Good or Do No Harm― Drugs, 2018, 78, 1567-1592.	10.9	8
62	Acute coronary syndromes in patients with angiographically normal or near normal (non-obstructive) coronary arteries. Trends in Cardiovascular Medicine, 2018, 28, 541-551.	4.9	17
63	Effect of Endurance Sport on the Right Heart. , 2018, , 157-165.		O
64	Cardiovascular safety of oncologic agents: A double-edged sword even in the era of targeted therapies $\hat{a} \in \text{``part 1.}$ Expert Opinion on Drug Safety, 2018, 17, 875-892.	2.4	14
65	Cardiovascular safety of oncologic agents: a double-edged sword even in the era of targeted therapies – Part 2. Expert Opinion on Drug Safety, 2018, 17, 893-915.	2.4	8
66	Myocardial Infarction of the Right Ventricle. , 2018, , 381-389.		0
67	Right Heart in Cardiac Pacing. , 2018, , 331-345.		O
68	Current Status of Renal Artery Angioplasty and Stenting for Resistant Hypertension: A Case Series and Review of the Literature. Current Hypertension Reviews, 2018, 13, 93-103.	0.9	4
69	Author`s Reply. Anatolian Journal of Cardiology, 2018, 19, 152-153.	0.9	1
70	Author`s Reply. Anatolian Journal of Cardiology, 2018, 19, 154.	0.9	0
71	Atrial antitachycardia pacing and atrial remodeling: A substudy of the international, randomized MINERVA trial. Heart Rhythm, 2017, 14, 1476-1484.	0.7	12
72	Hypertension and Cardiac Arrhythmias: Executive Summary of a Consensus Document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación CardÃaca y ElectrofisiologÃa (SOLEACE). European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 235-250.	3.0	50

#	Article	IF	CITATIONS
73	Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación CardÃaca y ElectrofisiologÃa (SOLEACE). Europace, 2017, 19, 891-911.	1.7	124
74	"Real life―longevity of implantable cardioverterâ€defibrillator devices. Clinical Cardiology, 2017, 40, 759-764.	1.8	28
75	Sudden death risk stratification in non-ischemic dilated cardiomyopathy using old and new tools: a clinical challenge. Expert Review of Cardiovascular Therapy, 2017, 15, 315-325.	1.5	7
76	Prevention of Cardiac Implantable Electronic Device Infections: Single Operator Technique with Use of Povidone″odine, Double Gloving, Meticulous Aseptic/Antiseptic Measures and Antibiotic Prophylaxis. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 26-34.	1,2	17
77	2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. Revista Espanola De Cardiologia (English Ed ), 2017, 70, 50.	0.6	280
78	Cryoballoon ablation of atrial fibrillation: a practical and effective approach. Clinical Cardiology, 2017, 40, 333-342.	1.8	16
79	Contemporary Diagnosis and Management of Atrial Flutter. Cardiology in Review, 2017, 25, 289-297.	1.4	11
80	Preâ€loading therapy with statins in patients with angina and acute coronary syndromes undergoing PCI. Journal of Interventional Cardiology, 2017, 30, 507-513.	1,2	17
81	Transcatheter aortic valve implantation economics: a grisly reality. Annals of Cardiothoracic Surgery, 2017, 6, 516-523.	1.7	17
82	Transcatheter aortic valve implantation in nonagenarians: selectively feasible or extravagantly futile?. Annals of Cardiothoracic Surgery, 2017, 6, 524-531.	1.7	4
83	Ablation of atrial fibrillation: single-shot techniques poised to dominate rhythm control strategies/the future is here. Journal of Thoracic Disease, 2017, 9, E313-E321.	1.4	11
84	Stroke Risk Stratification Schemes in Atrial Fibrillation in the Era of Non-Vitamin K Anticoagulants: Misleading and Obsolete, At Least for the "Low-Risk―Patients?. Current Drug Targets, 2017, 18, 1852-1865.	2.1	3
85	Transseptal Access to the Left Atrium: Tips and Tricks to Keep it Safe Derived from Single Operator Experience and Review of the Literature. Current Cardiology Reviews, 2017, 13, 305-318.	1.5	12
86	Impact of Percutaneous Closure of Interatrial Shunts on Migraine Attacks: Single-Operator Series and Review of the Literature. Reviews on Recent Clinical Trials, 2017, 12, 129-138.	0.8	6
87	Cardiac implantable electronic device lead extraction using the lead-locking device system: keeping it simple, safe, and inexpensive with mechanical tools and local anesthesia. Anatolian Journal of Cardiology, 2017, 18, 289-295.	0.9	8
88	The polymorphic deleted-form of the human $\hat{l}\pm 2B$ -adrenergic receptor and its wild-type counterpart display post-receptor signaling pathway differences in LLC-PK1 cells. Hellenic Journal of Cardiology, 2016, 57, 292-295.	1.0	1
89	Exercise and Arrhythmias: A Doubleâ€Edged Sword. PACE - Pacing and Clinical Electrophysiology, 2016, 39, 748-762.	1.2	15
90	Primary prevention of sudden cardiac death in Prinzmetal angina: The role of electrophysiology study in risk stratification. Hellenic Journal of Cardiology, 2016, 57, 205-209.	1.0	4

#	Article	IF	Citations
91	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Journal of Cardio-thoracic Surgery, 2016, 50, e1-e88.	1.4	754
92	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 2016, 37, 2893-2962.	2.2	5,689
93	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 2016, 18, 1609-1678.	1.7	3,523
94	Simplified swift and safe vascular closure device deployment without a local arteriogram: Single center experience in 2074 consecutive patients. Indian Heart Journal, 2016, 68, 529-538.	0.5	3
95	European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace, 2016, 18, 12-36.	1.7	66
96	European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. European Journal of Heart Failure, 2015, 17, 848-874.	7.1	32
97	Ranolazine and its Antiarrhythmic Actions. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2015, 13, 31-39.	1.0	9
98	Effects of enhanced pacing modalities on health care resource utilization and costs in bradycardia patients: An analysis of the randomized MINERVA trial. Heart Rhythm, 2015, 12, 1192-1200.	0.7	11
99	New-generation atrial antitachycardia pacing (Reactive ATP) is associated with reduced risk of persistent or permanent atrial fibrillation in patients with bradycardia: Results from the MINERVA randomized multicenter international trial. Heart Rhythm, 2015, 12, 1717-1725.	0.7	56
100	Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction. Circulation, 2015, 132, 1395-1403.	1.6	208
101	Rhythm or Rate Control Management of Atrial Fibrillation: An Overrated Dilemma. Hellenic Journal of Cardiology, 2015, 56, 495-500.	1.0	4
102	The clinical challenge of preventing sudden cardiac death immediately after acute ST-elevation myocardial infarction. Expert Review of Cardiovascular Therapy, 2014, 12, 1427-1437.	1.5	5
103	Atrial antitachycardia pacing and managed ventricular pacing in bradycardia patients with paroxysmal or persistent atrial tachyarrhythmias: the MINERVA randomized multicentre international trial. European Heart Journal, 2014, 35, 2352-2362.	2.2	111
104	Colchicine for prevention of atrial fibrillation recurrence after pulmonary vein isolation: Mid-term efficacy and effect on quality of life. Heart Rhythm, 2014, 11, 620-628.	0.7	110
105	Association of asymmetric dimethylarginine levels with treadmill-stress-test-derived prognosticators. Clinical Biochemistry, 2014, 47, 593-598.	1.9	5
106	Central Sympathetic Inhibition to Reduce Postablation Atrial Fibrillation Recurrences in Hypertensive Patients. Circulation, 2014, 130, 1346-1352.	1.6	27
107	Anti-Inflammatory Treatment With Colchicine inÂStable Chronic Heart Failure. JACC: Heart Failure, 2014, 2, 131-137.	4.1	108
108	Interatrial conduction time and incident atrial fibrillation: A prospective cohort study. Heart Rhythm, 2014, 11, 1095-1101.	0.7	18

#	Article	IF	CITATIONS
109	Prospective European Survey on Atrial Fibrillation Ablation: Clinical Characteristics of Patients and Ablation Strategies Used in Different Countries. Journal of Cardiovascular Electrophysiology, 2014, 25, 1074-1081.	1.7	22
110	Treating Dyslipidemias: Is Inflammation the Missing Link?. Medicinal Chemistry, 2014, 10, 643-652.	1.5	32
111	Cardiac resynchronization therapy: Dire need for targeted left ventricular lead placement and optimal device programming. World Journal of Cardiology, 2014, 6, 1270.	1.5	4
112	Electrical Storm: Clinical Management. , 2014, , 293-304.		0
113	Anticoagulation With Otamixaban and Ischemic Events in Non–ST-Segment Elevation Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2013, 310, 1145.	7.4	58
114	Colchicine Treatment for the Prevention of Bare-Metal Stent Restenosis in Diabetic Patients. Journal of the American College of Cardiology, 2013, 61, 1679-1685.	2.8	152
115	Renoprotective Effect of Remote Ischemic Post-Conditioning by Intermittent Balloon Inflations in Patients Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2013, 61, 1949-1955.	2.8	82
116	Combined Antiplatelet Therapy: Still a Sweeping Combination in Cardiology. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2013, 11, 136-167.	1.0	6
117	Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. New England Journal of Medicine, 2012, 367, 1297-1309.	27.0	765
118	Pathways for training and accreditation for transvenous lead extraction: a European Heart Rhythm Association position paper. Europace, 2012, 14, 124-134.	1.7	178
119	'Pathways for training and accreditation for transvenous lead extraction: a European Heart Rhythm Association position paper' [Europace 2012;14:124-134. doi: 10.1093/europace/eur338]. Europace, 2012, 14, 460-460.	1.7	12
120	Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2 -receptor antagonist: the DILIPO study. European Journal of Heart Failure, 2011, 13, 327-336.	7.1	38
121	1-Year Outcome of TRIAS HR (TRI-Stent Adjudication Study–High Risk of Restenosis). JACC: Cardiovascular Interventions, 2011, 4, 896-904.	2.9	49
122	Serum levels of ischemia modified albumin in overweight/obese postmenopausal women: A potential biomarker of atherosclerotic burden associated with oxidative stress. Maturitas, 2011, 70, 182-187.	2.4	13
123	Relation of Ventricular Tachycardia/Fibrillation to Beta-Blocker Dose Maximization Guided by Pacing Mode Analysis in Nonpacemaker-Dependent Patients With Implantable Cardioverter–Defibrillator. American Journal of Cardiology, 2011, 107, 1812-1817.	1.6	5
124	Should we measure routinely oxidised and atherogenic dense low-density lipoproteins in subjects with type 2 diabetes?. International Journal of Clinical Practice, 2010, 64, 1632-1642.	1.7	27
125	Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes. Angiology, 2010, 61, 584-590.	1.8	19
126	Lack of Association Between the Cholesteryl Ester Transfer Protein Gene—TaqlB Polymorphism and Coronary Restenosis Following Percutaneous Transluminal Coronary Angioplasty and Stenting: A Pilot Study. Angiology, 2010, 61, 338-343.	1.8	7

#	Article	IF	Citations
127	Novel sodium channel SCN5A mutations in Brugada syndrome patients from Greece. International Journal of Cardiology, 2010, 145, 45-48.	1.7	5
128	The Rationale and Design of the Perindopril Genetic Association Study (PERGENE): A Pharmacogenetic Analysis of Angiotensin-Converting Enzyme Inhibitor Therapy in Patients with Stable Coronary Artery Disease. Cardiovascular Drugs and Therapy, 2009, 23, 171-181.	2.6	27
129	Arrhythmogenic Right Ventricular Cardiomyopathy in an Octogenarian Presenting with Ventricular Tachycardia. PACE - Pacing and Clinical Electrophysiology, 2009, 32, e43-7.	1.2	4
130	Correlation of Mechanical Dyssynchrony with QRS Duration Measured by Signalâ€Averaged Electrocardiography. Annals of Noninvasive Electrocardiology, 2009, 14, 234-241.	1.1	9
131	Ischemia modified albumin, high-sensitivity c-reactive protein and natriuretic peptide in patients with coronary atherosclerosis. Clinica Chimica Acta, 2009, 408, 65-69.	1.1	29
132	Design and rationale of the TRI-stent Adjudication Study (TRIAS) Program. American Heart Journal, 2009, 158, 527-532.e1.	2.7	14
133	Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine, 2009, 361, 1045-1057.	27.0	6,019
134	Dabigatran versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2009, 361, 1139-1151.	27.0	9,839
135	Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet, The, 2009, 374, 1840-1848.	13.7	548
136	Association of the 894G>T polymorphism in the endothelial nitric oxide synthase gene with risk of acute myocardial infarction. BMC Medical Genetics, 2008, 9, 43.	2.1	23
137	The MINERVA study design and rationale: A controlled randomized trial to assess the clinical benefit of minimizing ventricular pacing in pacemaker patients with atrial tachyarrhythmias. American Heart Journal, 2008, 156, 445-451.	2.7	24
138	Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2008, 372, 807-816.	13.7	934
139	Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet, The, 2008, 372, 817-821.	13.7	694
140	An unusual distal abdominal migration of a pacemaker pulse generator with a complete epicardial lead fracture. Europace, 2008, 10, 1461-1461.	1.7	3
141	Removal of a temporary pacemaker lead fragment with the use of biopsy forceps. Europace, 2008, 11, 131-131.	1.7	0
142	Alternate Site Pacing in Patients at Risk for Heart Failure. Angiology, 2008, 59, 97S-102S.	1.8	8
143	Study of Left Ventricular Long Axis Function in Patients with Hypertensive Response to Exercise. Hypertension Research, 2008, 31, 1485.	2.7	0
144	The BEAUTIFUL Study: Randomized Trial of Ivabradine in Patients with Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction – Baseline Characteristics of the Study Population. Cardiology, 2008, 110, 271-282.	1.4	39

#	Article	IF	Citations
145	Letter by Tsilakis et al Regarding Article "Subclinical Left Ventricular Longitudinal Systolic Dysfunction in Hypertension With No Evidence of Heart Failure". Circulation Journal, 2008, 72, 1037.	1.6	2
146	Left ventricular long-axis dysfunction in hypertensive patients. Journal of Hypertension, 2008, 26, 1497.	0.5	0
147	ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovascular Research, 2007, 73, 237-246.	3.8	146
148	End-inspiratory occlusion maneuver during transesophageal echocardiography for patent foramen ovale detection in intensive care unit patients. Intensive Care Medicine, 2007, 33, 1458-1462.	8.2	11
149	Cardiac resynchronisation therapy in heart failure patients with narrow QRS complex: quo vadis?. Hellenic Journal of Cardiology, 2007, 48, 315-8.	1.0	1
150	Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet, The, 2006, 367, 569-578.	13.7	639
151	Congestive Heart Failure and Anemia. Transfusion Alternatives in Transfusion Medicine, 2006, 8, 15-16.	0.2	0
152	Mo-P1:99 Serum levels of oxidized low density lipoprotein relate to the extent and severity of coronary atherosclerosis in patients with coronary syndromes. Atherosclerosis Supplements, 2006, 7, 67.	1.2	0
153	Mo-P4:266 A simple peripheral atherosclerosis scoring system can readily predict the severity of coronary artery disease. Atherosclerosis Supplements, 2006, 7, 104-105.	1.2	0
154	Coronary risk factors and inflammation in patients with coronary artery disease and internal cardioverter defibrillator implants. International Journal of Cardiology, 2006, 112, 72-79.	1.7	4
155	Ivabradine: a Selective If Current Inhibitor in the Treatment of Stable Angina. Recent Patents on Cardiovascular Drug Discovery, 2006, 1, 277-282.	1.5	8
156	Multi-Center Clinical Experience with a Lumenless, Catheter-Delivered, Bipolar, Permanent Pacemaker Lead: Implant Safety and Electrical Performance. PACE - Pacing and Clinical Electrophysiology, 2006, 29, 858-865.	1.2	74
157	Improving SVT Discrimination in Single-Chamber ICDs: A New Electrogram Morphology-Based Algorithm. Journal of Cardiovascular Electrophysiology, 2006, 17, 1310-1319.	1.7	87
158	Wide-QRS-Complex Tachycardia with a Negative Concordance Pattern in the Precordial Leads: Are the ECG Criteria Always Reliable?. PACE - Pacing and Clinical Electrophysiology, 2006, 29, 63-66.	1.2	9
159	The Deleterious Consequences of Right Ventricular Apical Pacing: Time to Seek Alternate Site Pacing. PACE - Pacing and Clinical Electrophysiology, 2006, 29, 298-315.	1.2	137
160	Transcatheter closure of patent foramen ovale during a radiofrequency ablation procedure. Clinical Cardiology, 2006, 29, 369-371.	1.8	1
161	Rethinking Target Discovery in Polygenic Diseases. Current Topics in Medicinal Chemistry, 2006, 6, 1791-1798.	2.1	19
162	Site of successful slow pathway ablation relates to clinical tachycardia rate in patients with atrioventricular nodal re-entrant tachycardia. Heart, 2006, 92, 115-116.	2.9	6

#	Article	IF	CITATIONS
163	Lack of association between α2B-adrenergic receptor polymorphism and risk of restenosis following coronary angioplasty and stent implantation – preliminary report. Clinical Chemistry and Laboratory Medicine, 2006, 44, 807-12.	2.3	3
164	Efficacy of antithrombotic therapy in chronic heart failure: The HELAS study. European Journal of Heart Failure, 2006, 8, 428-432.	7.1	191
165	The contrOL of dYslipideMia in outPatlent clinics in GreeCe (Olympic) Study. Angiology, 2005, 56, 731-741.	1.8	19
166	Renal tumour with cavoatrioventricular extension. Heart, 2005, 91, 9-9.	2.9	4
167	Erythropoietin in Heart Failure and Other Cardiovascular Diseases: Hematopoietic and Pleiotropic Effects. Current Drug Targets Cardiovascular & Haematological Disorders, 2005, 5, 355-375.	2.0	28
168	Aspirin and Clopidogrel: A Sweeping Combination in Cardiology. Current Medicinal Chemistry Cardiovascular and Hematological Agents, 2005, 3, 203-219.	1.7	19
169	Well-Functioning Double-Orifice Mitral Valve in a Young Woman with Marfan-Like Habitus and Atrial Tachycardia. Cardiology, 2005, 104, 169-170.	1.4	2
170	Effects of oral pirenzepine on heart rate variability after acute myocardial infarction: A randomized trial. Heart Rhythm, 2005, 2, S305.	0.7	0
171	Transvenous permanent pacing lead placement in the presence of prosthetic metallic tricuspid and mitral valves. Heart Rhythm, 2005, 2, S60.	0.7	0
172	Effects of Two Nebulization Regimens on Heart Rate Variability During Acute Asthma Exacerbations in Children. Journal of Asthma, 2005, 42, 273-279.	1.7	13
173	Release of endothelin-1 from human endocardium after radiofrequency catheter ablation and coronary angioplasty: comparative results. International Journal of Cardiology, 2005, 102, 187-193.	1.7	8
174	Accuracy of pulmonary function tests in predicted exercise capacity in COPD patients. Respiratory Medicine, 2005, 99, 609-614.	2.9	10
175	The contribution of echocardiography to cardiac resynchronisation therapy. Hellenic Journal of Cardiology, 2005, 46, 289-99.	1.0	2
176	Enzyme Replacement Therapy in Severe Fabry Disease with Renal Failure: A 1-year Follow-up. Acta Dermato-Venereologica, 2004, 84, 389-392.	1.3	5
177	Autonomic responses to single- and dual-chamber pacing. American Journal of Cardiology, 2004, 93, 985-989.	1.6	12
178	Cardiac resynchronization therapy in congestive heart failure: Ready for prime time?. Heart Rhythm, 2004, 1, 355-363.	0.7	24
179	Ibutilide added to propafenone for the conversion of atrial fibrillation and atrial flutter. Journal of the American College of Cardiology, 2004, 44, 859-863.	2.8	35
180	Clinical and pharmacological significance of $\hat{l}\pm 2$ -adrenoceptor polymorphisms in cardiovascular diseases. International Journal of Cardiology, 2004, 97, 367-372.	1.7	32

#	Article	IF	CITATIONS
181	Pulmonary valve staphylococcal endocarditis in a nondrug addict with alcoholic cirrhosis. International Journal of Cardiology, 2004, 97, 575-576.	1.7	3
182	The bezold-jarisch reflex in acute inferior myocardial infarction: Clinical and sympathovagal spectral correlates. Clinical Cardiology, 2003, 26, 323-328.	1.8	25
183	Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet, The, 2003, 362, 782-788.	13.7	1,952
184	P1548 Usefulness of ibutitilide in combination with propafenone for the conversion of atrial fibrillation. European Heart Journal, 2003, 24, 280.	2.2	10
185	Right ventricular cardiomyopathy in β-thalassaemia major. European Heart Journal, 2002, 23, 147-156.	2.2	74
186	Arrhythmia recurrences are rare when the site of radiofrequency ablation of the slow pathway is medial or anterior to the coronary sinus os. Europace, 2002, 4, 193-199.	1.7	8
187	Single-lead VDD-pacing system incorporating high impedance stimulation: a multicentre study. Europace, 2002, 4, 129-135.	1.7	1
188	Contribution of the sT elevation/T-wave normalization in q-wave leads during routine, pre-discharge treadmill exercise test to patient management and risk stratification after acute myocardial infarction. Journal of the American College of Cardiology, 2002, 40, 62-70.	2.8	9
189	Silent cardiac echinococcosis. Lancet Infectious Diseases, The, 2002, 2, 367.	9.1	0
190	Comparative three-year performance of chronic atrial sensing among eight different VDD systems. American Journal of Cardiology, 2002, 89, 1215-1218.	1.6	7
191	Right ventricular diastolic function in $\hat{l}^2$ -thalassemia major: Echocardiographic and clinical correlates. American Heart Journal, 2001, 141, 428-434.	2.7	59
192	Intravenous magnesium sulfate versus diltiazem in paroxysmal atrial fibrillation. International Journal of Cardiology, 2001, 79, 287-291.	1.7	51
193	Autonomic Patterns Preceding and Following Accelerated Idioventricular Rhythm in Acute Myocardial Infarction. Cardiology, 2001, 96, 24-31.	1.4	12
194	Ancillary Tools in Pacemaker and Defibrillator Lead Extraction Using a Novel Lead Removal System. PACE - Pacing and Clinical Electrophysiology, 2001, 24, 282-287.	1.2	14
195	The Prognostic Significance of Atrial Arrhythmias Recorded Early After Cardioversion for Atrial Fibrillation. PACE - Pacing and Clinical Electrophysiology, 2001, 24, 1076-1081.	1.2	9
196	Reduced incidence of clinical restenosis with newer generation stents, stent oversizing, and highâ€pressure deployment: Singleâ€operator experience. Clinical Cardiology, 2001, 24, 119-126.	1.8	10
197	Diagnostic superiority of continuousâ€loop electrocardiographic recording over other testing in a patient with recurrent syncope and underlying coronary artery disease with severe left ventricular dysfunction. Clinical Cardiology, 2001, 24, 419-421.	1.8	0
198	Usefulness of reperfusion ventricular arrhythmias in non-invasive prediction of early reperfusion and sustained coronary artery patency in acute myocardial infarction. Journal of Thrombosis and Thrombolysis, 2001, 12, 231-236.	2.1	10

#	Article	IF	CITATIONS
199	VDD pacing from the middle cardiac vein via a persistent left superior vena cava. International Journal of Cardiovascular Imaging, 2001, 17, 329-331.	0.6	5
200	Radiofrequency ablation in pediatric and adult patients: comparative results. Journal of Interventional Cardiac Electrophysiology, 2001, 5, 443-453.	1.3	18
201	Correction for Heart Rate Is Not Necessary for QT Dispersion in Individuals without Structural Heart Disease and Patients with Ventricular Tachycardia. Annals of Noninvasive Electrocardiology, 2001, 7, 47-52.	1.1	6
202	In-vivo testing of digital cellular telephones in patients with implantable cardioverter-defibrillators. European Heart Journal, 2001, 22, 1337-1342.	2.2	23
203	Weight loss after bariatric surgery normalizes Aortic distensibility and left ventricular function in subjects with morbid obesity Ignatios Ikonomidis, Andreas Mazarakis, Ioannis Chiladakis, Periklis Davlouros, George Hahalis, Costas Evdoridis, Fotis Kalfarentzos, Antonis S. Manolis. University of Patras. Patras, Greece, Journal of the American College of Cardiology, 2001, 37, A255.	2.8	0
204	Coronary artery calcification in patients with acute chest pain Dimitris Alexopoulos, Christos Stathopoulos, George Hahalis, John A. Chiladakis, Abraham Kotsaridis, Antonis S. Manolis. Patras University, Patras, Greece. Journal of the American College of Cardiology, 2001, 37, A377.	2.8	0
205	Two-Coil Versus Single-Coil Transvenous Cardioverter Defibrillator Systems: Comparative Data. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 1999-2002.	1.2	10
206	Electrophysiologist-Implanted Transvenous Cardioverter Defibrillators Using Local Versus General Anesthesia. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 96-105.	1.2	23
207	Significance of r-on-t phenomenon in early ventricular tachyarrhythmia susceptibility after acute myocardial infarction in the thrombolytic era. American Journal of Cardiology, 2000, 85, 289-293.	1.6	23
208	Effects of early captopril therapy after myocardial infarction on the incidence of late potentials. Clinical Cardiology, 2000, 23, 96-102.	1.8	6
209	Dispersion of ventricular repolarization is determined by the presence of myocardial viability in patients with old myocardial infarction. A dobutamine stress echocardiography study. European Heart Journal, 2000, 21, 446-456.	2.2	13
210	Pectoral Cardioverter Defibrillators: Comparison of Prepectoral and Submuscular Implantation Techniques. PACE - Pacing and Clinical Electrophysiology, 1999, 22, 469-478.	1.2	18
211	LETTERS TO THE EDITOR. PACE - Pacing and Clinical Electrophysiology, 1999, 22, 1274-1274.	1.2	3
212	Radiofrequency ablation in older children and adolescents by an adult electrophysiology team. Journal of Interventional Cardiac Electrophysiology, 1999, 3, 79-86.	1.3	8
213	Percutaneous extraction of transvenous defibrillator leads using the VascoExtor pacing lead removal system. Journal of Interventional Cardiac Electrophysiology, 1999, 3, 247-251.	1.3	10
214	Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet, The, 1999, 354, 716-722.	13.7	792
215	Detection of myocardial injury during radiofrequency catheter ablation by measuring serum cardiac troponin I levels: procedural correlates. Journal of the American College of Cardiology, 1999, 34, 1099-1105.	2.8	55
216	Unusual Features of Right and Left Idiopathic Ventricular Tachycardia Aholished hy Radiofrequency Catheter Ablation. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 1831-1834.	1.2	12

#	Article	IF	CITATIONS
217	Pretreatment with Antithrombotic Agents During Radiofrequency Catheter Ablation: A Randomized Comparison of Aspirin Versus Ticlopidine. Journal of Cardiovascular Electrophysiology, 1998, 9, 1144-1151.	1.7	28
218	Successful Percutaneous Extraction of Pacemaker Leads With a Novel (VascoExtor) Pacing Lead Removal System. American Journal of Cardiology, 1998, 81, 935-938.	1.6	23
219	Idiopathic long QT syndrome with late onset of bradycardia-dependent and short-coupled variant of torsade de pointes. International Journal of Cardiology, 1998, 64, 93-95.	1.7	4
220	Beat-to-beat wavelet variance of the QRS complex as a marker of arrhythmogenic substrate in ventricular tachycardia patients. Physiological Measurement, 1998, 19, 77-92.	2.1	12
221	Atrial Arrhythmias Early After Cardioversion Predict Recurrence of Atrial Fibrillation. Journal of the American College of Cardiology, 1998, 31, 184A.	2.8	0
222	Randomized Comparison of the Effect of Aspirin Versus Ticlopidine on the Thrombogenic Potential of Radiofrequency Ablation. Journal of the American College of Cardiology, 1998, 31, 254A.	2.8	1
223	Altered Mitral Flow Pattern in Patients With Hypertrophic Obstructive Cardiomyopathy. Circulation, 1998, 98, .	1.6	0
224	Comparison of Signal-Averaged Electrocardiograms with Different Levels of Noise: Time-Domain, Frequency-Domain, and Spectrotemporal Analysis. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 671-682.	1.2	1
225	Successful Radiofrequency Catheter Ablation of Automatic Atrial Tachycardia with Regression of the Cardiomyopathy Picture. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 953-959.	1.2	41
226	Pretreatment With Aspirin and Ticlopidine Confers Lower Thrombogenic Potential of Radiofrequency Catheter Ablation. American Journal of Cardiology, 1997, 79, 494-497.	1.6	22
227	Abnormal signalâ€everaged electrocardiograms in patients with incomplete right bundleâ€branch block. Clinical Cardiology, 1997, 20, 17-22.	1.8	17
228	Transvenous defibrillator systems implanted by electrophysiologists in the catheterization laboratory. Clinical Cardiology, 1997, 20, 117-124.	1.8	12
229	Thrombogenicity of radiofrequency lesions: Results with serial D-dimer determinations. Journal of the American College of Cardiology, 1996, 28, 1257-1261.	2.8	49
230	Perioperative and Long-term Results With Mapping-Guided Subendocardial Resection and Left Ventricular Endoaneurysmorrhaphy. Circulation, 1996, 94, 1041-1048.	1.6	42
231	Implantable Cardioverter-Defibrillators. Journal of Clinical Engineering, 1995, 20, 205-210.	0.1	0
232	Radiofrequency Ablation of Atrial Insertion of Left-Sided Accessory Pathways Guided by the "W Sign". Journal of Cardiovascular Electrophysiology, 1995, 6, 1068-1076.	1.7	10
233	Radiofrequency Catheter Ablation for Cardiac Tachyarrhythmias. Annals of Internal Medicine, 1994, 121, 452.	3.9	60
234	Transvenous Endocardial Cardioverter Defibrillator Systems. Archives of Internal Medicine, 1994, 154, 617.	3.8	8

#	Article	IF	CITATIONS
235	Antitachycardia pacing and low-energy cardioversion for ventricular tachycardia termination: A clinical perspective. American Heart Journal, 1994, 127, 1038-1046.	2.7	27
236	Fully transvenous cardioverter defibrillators: Rare need for subcutaneous patch with two newer-generation systems. American Heart Journal, 1994, 128, 808-815.	2.7	9
237	Radiofrequency ablation of left-sided accessory pathways: Transaortic versus transseptal approach. American Heart Journal, 1994, 128, 896-902.	2.7	33
238	Transvenous endocardial cardioverter defibrillator systems. Is the future here?. Archives of Internal Medicine, 1994, 154, 617-622.	3.8	7
239	Effects of Coronary Artery Bypass Grafting on Ventricular Arrhythmias: Results with Electrophysiological Testing and Long-Term Follow-Up. PACE - Pacing and Clinical Electrophysiology, 1993, 16, 984-991.	1.2	42
240	Plasma level changes of fibrinopeptide a after uncomplicated coronary angioplasty. Clinical Cardiology, 1993, 16, 548-552.	1.8	11
241	Magnetic Field Interference in High-Resolution Electrocardiography. Journal of Cardiovascular Electrophysiology, 1992, 3, 34-39.	1.7	0
242	Electrophysiological and electropharmacological studies in pre-excitation syndromes: results with propafenone therapy and isoproterenol infusion testing. European Heart Journal, 1992, 13, 1489-1495.	2.2	13
243	Cost-effectiveness of the implantable cardioverter-defibrillator: Effect of improved battery life and comparison with amiodarone therapy. Journal of the American College of Cardiology, 1992, 19, 1323-1334.	2.8	103
244	Effect of Successful Coronary Angioplasty on the Signal-Averaged Electrocardiogram. PACE - Pacing and Clinical Electrophysiology, 1992, 15, 950-956.	1.2	3
245	Limited clinical utility of endomyocardial biopsy in patients presenting with ventricular tachycardia without apparent structural heart disease. Clinical Cardiology, 1992, 15, 24-28.	1.8	9
246	Inappropriate Shocks and Elevation of Defibrillation Thresholds in a Patient with Automatic Defibrillator Patch Silastic Erosion and Titanium Mesh Fraying. PACE - Pacing and Clinical Electrophysiology, 1991, 14, 1452-1455.	1.2	6
247	Syncope: Current Diagnostic Evaluation and Management. Annals of Internal Medicine, 1990, 112, 850.	3.9	193
248	Value of programmed ventricular stimulation in the evaluation and management of patients with nonsustained ventricular tachycardia associated with coronary artery disease. American Journal of Cardiology, 1990, 65, 201-205.	1.6	35
249	Electrophysiologic and electrocardiographic effects, efficacy and safety of encainide in malignant ventricular arrhythmias associated with coronary artery disease. American Journal of Cardiology, 1990, 66, 947-953.	1.6	5
250	Randomized doubleâ€blind study of intravenous tocainide versus lidocaine for suppression of ventricular arrhythmias after cardiac surgery. Clinical Cardiology, 1990, 13, 177-181.	1.8	3
251	Mexiletine: Pharmacology and therapeutic use. Clinical Cardiology, 1990, 13, 349-359.	1.8	59
252	Automatic Implantable Cardioverter Defibrillator. JAMA - Journal of the American Medical Association, 1989, 262, 1362.	7.4	28

#	Article	IF	Citations
253	Prognostic value of early electrophysiologic studies for ventricular tachycardia recurrence in patients with coronary artery disease treated with amiodarone. American Journal of Cardiology, 1989, 63, 1052-1057.	1.6	34
254	Electrophysiologic effects, efficacy and tolerance of class Ic antiarrhythmic agents in Wolff-Parkinson-White syndrome. American Journal of Cardiology, 1989, 63, 746-750.	1.6	12
255	External cardiac programmed stimulation for noninvasive termination of sustained supraventricular and ventricular tachycardia. American Journal of Cardiology, 1989, 63, 177-183.	1.6	23
256	Reversal of electrophysiologic effects of flecainide on the accessory pathway by isoproterenol in the Wolff-Parkinson-White syndrome. American Journal of Cardiology, 1989, 64, 194-198.	1.6	33
257	Clinical experience in seventy-seven patients with the automatic implantable cardioverter defibrillator. American Heart Journal, 1989, 118, 445-450.	2.7	112
258	Therapeutic serum lidocaine and metabolite concentrations in patients undergoing electrophysiologic study after discontinuation of intravenous lidocaine infusion. American Heart Journal, 1989, 117, 1060-1064.	2.7	18
259	Surgical therapy for drug-refractory ventricular tachycardia: Results with mapping-guided subendocardial resection. Journal of the American College of Cardiology, 1989, 14, 199-208.	2.8	24
260	Prophylactic automatic implantable cardioverter-defibrillator patches in patients at high risk for postoperative ventricular tachyarrhythmias. Journal of the American College of Cardiology, 1989, 13, 1367-1373.	2.8	23
261	Pacemakers and Exercise Current Status, Future Developments and Practical Implications of Physiological Pacemakers. Sports Medicine, 1989, 8, 1-8.	6.5	22
262	Automatic implantable cardioverter defibrillator. Current status. JAMA - Journal of the American Medical Association, 1989, 262, 1362-1368.	7.4	26
263	Sensitivity and specificity of programmed atrial stimulation for induction of supraventricular tachycardias. Clinical Cardiology, 1988, 11, 307-310.	1.8	9
264	Necropsy study of right atrial appendage: Morphology and quantitative measurements. Clinical Cardiology, 1988, 11, 788-792.	1.8	13
265	Echocardiographic and Clinical Correlates in Drug Addicts With Infective Endocarditis. Archives of Internal Medicine, 1988, 148, 2461.	3.8	24
266	Echocardiographic and clinical correlates in drug addicts with infective endocarditis. Implications of vegetation size. Archives of Internal Medicine, 1988, 148, 2461-2465.	3.8	8
267	Hypothyroid Cardiac Tamponade. Archives of Internal Medicine, 1987, 147, 1167.	3.8	40
268	Atypical Pulmonary and Neurologic Complications of Amiodarone in the Same Patient. Archives of Internal Medicine, 1987, 147, 1805.	3.8	23
269	Supraventricular Tachycardia. Archives of Internal Medicine, 1987, 147, 1706.	3.8	30
270	Cardiopathia fantastica and arteritis factitia as manifestations of Munchausen syndrome. Critical Care Medicine, 1987, 15, 526-529.	0.9	6

#	Article	IF	CITATIONS
271	Shortâ€Term Hemodynamic Effects of Intravenous Methyldopa in Patients with Congestive Heart Failure. Pharmacotherapy, 1987, 7, 216-222.	2.6	12
272	Orthostatic hypotension due to quinidine and atenolol. American Journal of Medicine, 1987, 82, 1083-1084.	1.5	2
273	Childhood periodic paralysis with dysrhythmias: Electrophysiologic and histopathologic evaluation. American Heart Journal, 1987, 114, 187-189.	2.7	3
274	Pacemaker Wenckebach secondary to variable latency: An unusual form of hyperkalemic pacemaker exit block. American Heart Journal, 1987, 114, 189-192.	2.7	16
275	Atypical pulmonary and neurologic complications of amiodarone in the same patient. Report of a case and review of the literature. Archives of Internal Medicine, 1987, 147, 1805-1809.	3.8	4
276	Hypothyroid cardiac tamponade. Archives of Internal Medicine, 1987, 147, 1167-1169.	3.8	2
277	Supraventricular tachycardia. Mechanisms and therapy. Archives of Internal Medicine, 1987, 147, 1706-1716.	3.8	O
278	Comparison of heart rate variability parameters calculated by two different commercial analysis systems. , 0, , .		0
279	Short-term reproducibility of the time and frequency domain parameters of heart rate variability. , 0, , .		O
280	Selective noise filtering of high resolution ECG through wavelet transform. , 0, , .		0